id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-266313-b518n9dx	Cao, Yu-chen	Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence	2020-04-02		.txt	text/plain	5557	226	45	bioRxiv; 2020 Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile Pathological findings of COVID-19 associated with acute respiratory distress syndrome SARS-CoV-2 viral load in upper respiratory specimens of infected patients GS-5734) protects African green monkeys from Nipah virus challenge The antiviral compound remdesivir potently inhibits RNAdependent RNA polymerase from Middle East respiratory syndrome coronavirus Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection Nucleotide prodrug GS-5734 is a broad-spectrum filovirus inhibitor that provides complete therapeutic protection against the development of Ebola virus disease (EVD) in infected non-human primates Summaries of evidence from selected experimental therapeutics A randomized, controlled trial of Ebola virus disease therapeutics The pathogenesis of Ebola virus disease Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys Nucleosides for the treatment of respiratory RNA virus infections The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures COVID-19 control in China during mass population movements at New Year Remdesivir as a possible therapeutic option for the COVID-19 Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides Travel Medicine and Infectious Disease xxx The 53% fatality rate was not significantly different from the average 50% fatality rate of Ebola virus infection, and as a result, phase II clinical trials were stopped.	cache/cord-266313-b518n9dx.txt	txt/cord-266313-b518n9dx.txt
